SRR35579849
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.450
- HYPOXIA+0.420
- MYC_TARGETS_V2+0.390
- GLYCOLYSIS+0.360
- MTORC1_SIGNALING+0.360
- G2M_CHECKPOINT+0.350
- PROTEIN_SECRETION+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.320
- E2F_TARGETS+0.290
- HEDGEHOG_SIGNALING+0.290
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.260
- ALLOGRAFT_REJECTION-0.210
- ESTROGEN_RESPONSE_LATE-0.160
- IL2_STAT5_SIGNALING-0.150
- COAGULATION-0.140
- BILE_ACID_METABOLISM-0.110
- COMPLEMENT-0.110
- IL6_JAK_STAT3_SIGNALING-0.110
- ADIPOGENESIS-0.080
- INFLAMMATORY_RESPONSE-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696793 | — | — | 0.820 |
| 2 | SRR12696801 | — | — | 0.805 |
| 3 | SRR12696773 | — | — | 0.802 |
| 4 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.785 |
| 5 | MNG296 | — | — | 0.781 |
| 6 | TCGA-51-6867-01A-11R-2045-07 | — | cohortSQ2 | 0.779 |
| 7 | R418 | — | — | 0.778 |
| 8 | SRR9879279 | — | cohortA1 | 0.767 |
| 9 | 131484 | EPN | Supratentorial EPN | 0.760 |
| 10 | TCGA-56-1622-01A-01R-0692-07 | — | cohortSQ1 | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |